Patriot Financial Group Insurance Agency LLC Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Patriot Financial Group Insurance Agency LLC boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,383 shares of the medical research company’s stock after purchasing an additional 661 shares during the quarter. Patriot Financial Group Insurance Agency LLC’s holdings in IQVIA were worth $1,451,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Capital Performance Advisors LLP acquired a new stake in IQVIA during the third quarter worth $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA during the 3rd quarter worth about $28,000. Avior Wealth Management LLC grew its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. boosted its stake in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after buying an additional 196 shares during the period. Finally, UMB Bank n.a. increased its position in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 99 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on IQV shares. Barclays cut their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Bank of America reduced their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Robert W. Baird lowered their target price on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Finally, Evercore ISI reduced their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Stock Up 1.5 %

Shares of IQV stock opened at $207.34 on Tuesday. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock’s 50 day simple moving average is $199.71 and its 200 day simple moving average is $221.18. The company has a market capitalization of $37.63 billion, a price-to-earnings ratio of 27.29, a PEG ratio of 2.14 and a beta of 1.48. IQVIA Holdings Inc. has a twelve month low of $187.62 and a twelve month high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.